publication venue for
- Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 2023
- External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension. 2023
- Characteristics of incidental prostate cancer in the United States. 2023
- Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. 2023
- Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate. 2023
- Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.. 26. 2022
- A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).. 25. 2022
- Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).. 25. 2022
- Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.. 25. 2021
- Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. 2021
- Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI).. 24. 2020
- Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States.. 23. 2020
- Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.. 23. 2020
- Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy.. 23. 2020
- Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.. 23. 2019
- Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies.. 23. 2019
- Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. 22. 2019
- Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.. 22. 2018
- Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram.. 21. 2018
- Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.. 21. 2018
- Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy.. 21. 2017
- Molecular alterations in prostate cancer and association with MRI features.. 20. 2017
- Periprostatic adipose inflammation is associated with high-grade prostate cancer.. 20. 2017
- Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.. 20. 2017
- Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.. 20. 2017
- Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study.. 20. 2017
- Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy.. 20. 2016
- Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.. 19. 2016
- Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.. 19. 2016
- The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.. 19. 2016
- In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI.. 19. 2016
- Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection.. 19. 2015
- Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.. 18. 2015
- The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices.. 18. 2014
- The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.. 17. 2014
- Androgen dynamics and serum PSA in patients treated with abiraterone acetate.. 17. 2014
- Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.. 17. 2013
- Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy.. 16. 2013
- Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.. 16. 2013
- The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.. 13. 2010
- Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.. 11. 2007
- Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy.. 7. 2004
- Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible.. 6. 2003
- In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.. 5. 2002
- The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer.. 5. 2002
- Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.. 4. 2001
- The impact of sexual and urinary dysfunction on health-related quality-of-life (HRQOL) following radical prostatectomy (RP).. 3. 2000
- Clinical and pathologic significance of T1c adenocarcinoma of the prostate cancer.. 2. 1999
- Editorial.. 2. 1999
- Editorial.. 2. 1999
- Editorial.. 2. 1999
- Pathologic progression of autochthonous prostate cancer in the TRAMP model.. 2. 1999
- The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.. 2. 1999
- Editorial.. 1. 1998
- Unravelling the confusions in prostatic disease.. 1. 1998
- Editorial.. 1. 1997
- Editorial.. 1. 1997
- Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen.. 1. 1997
- PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. 2021
- Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. 2020
- Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. 2019
- The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. 2016
- The very-high-risk prostate cancer: a contemporary update. 2016
- Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. 2009
- Exercise therapy across the prostate cancer continuum. 2009
- New circulating biomarkers for prostate cancer. 2007
- Photoselective vaporization of the prostate (GreenLight PV): lessons learnt after 3500 procedures. 2007
- The emerging role of the PI3-K-Akt pathway in prostate cancer progression. 2005
- Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. 2022
- Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. 2022
- Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. 2022
- Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 2021